Banco Santander S.A. trimmed its position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 32.3% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 736,901 shares of the biopharmaceutical company's stock after selling 351,415 shares during the quarter. Banco Santander S.A.'s holdings in Bristol Myers Squibb were worth $45,983,000 at the end of the most recent reporting period.
A number of other large investors also recently modified their holdings of the company. BlackRock Inc. raised its holdings in shares of Bristol Myers Squibb by 5.1% in the 2nd quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company's stock worth $10,393,783,000 after acquiring an additional 8,702,106 shares during the last quarter. State Street Corp boosted its stake in Bristol Myers Squibb by 7.3% during the 2nd quarter. State Street Corp now owns 105,757,638 shares of the biopharmaceutical company's stock valued at $6,093,755,000 after purchasing an additional 7,192,724 shares during the last quarter. Primecap Management Co. CA acquired a new position in Bristol Myers Squibb during the 2nd quarter valued at about $1,436,115,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Bristol Myers Squibb by 0.5% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 22,839,010 shares of the biopharmaceutical company's stock valued at $1,315,984,000 after purchasing an additional 119,690 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in Bristol Myers Squibb by 2.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 18,762,589 shares of the biopharmaceutical company's stock worth $1,137,847,000 after purchasing an additional 520,330 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors.
Insider Activity at Bristol Myers Squibb
In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the firm's stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the sale, the senior vice president directly owned 16,862 shares of the company's stock, valued at $1,138,185. This trade represents a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Julia A. Haller sold 3,800 shares of the business's stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $63.31, for a total value of $240,578.00. Following the completion of the sale, the director owned 30,279 shares in the company, valued at approximately $1,916,963.49. The trade was a 11.15% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.05% of the stock is currently owned by corporate insiders.
Wall Street Analyst Weigh In
Several analysts have recently commented on the company. Guggenheim reissued a "buy" rating and issued a $75.00 price objective (up from $72.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. Wells Fargo & Company cut their target price on Bristol Myers Squibb from $65.00 to $60.00 and set an "equal weight" rating on the stock in a research report on Tuesday, October 13th. Piper Sandler cut their target price on Bristol Myers Squibb from $82.00 to $78.00 and set an "overweight" rating on the stock in a research report on Monday, October 26th. BMO Capital Markets reiterated a "market perform" rating on shares of Bristol Myers Squibb in a report on Monday, July 27th. Finally, Truist Financial set a $70.00 price target on Bristol Myers Squibb in a research report on Friday, October 30th. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, sixteen have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Bristol Myers Squibb presently has an average rating of "Hold" and a consensus target price of $65.46.
View Our Latest Stock Analysis on BMY
Bristol Myers Squibb Trading Down 0.7%
NYSE BMY opened at $62.96 on Tuesday. The stock has a market capitalization of $128.69 billion, a price-to-earnings ratio of 10.00, a PEG ratio of 0.32 and a beta of 0.20. Bristol Myers Squibb Company has a one year low of $45.26 and a one year high of $68.64. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.59 and a quick ratio of 1.44. The business's fifty day moving average is $61.82 and its 200-day moving average is $60.35.
Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 earnings per share for the quarter, beating the consensus estimate of $1.10 by $0.25. Bristol Myers Squibb had a net margin of 18.47% and a return on equity of 60.48%. The company had revenue of $13.07 billion during the quarter, compared to analyst estimates of $12.72 billion. During the same quarter in the prior year, the business earned $1.63 earnings per share. The firm's revenue for the quarter was up 6.9% on a year-over-year basis. Equities research analysts predict that Bristol Myers Squibb Company will post 6.46 EPS for the current year.
Bristol Myers Squibb Announces Dividend
The company also recently disclosed a quarterly dividend, which was paid on Monday, November 2nd. Investors of record on Friday, October 2nd were paid a $0.63 dividend. The ex-dividend date was Friday, October 2nd. This represents a $2.52 annualized dividend and a yield of 4.0%. Bristol Myers Squibb's dividend payout ratio is presently 55.88%.
About Bristol Myers Squibb
(
Free Report)
Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease. The company's medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.
Read More
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Bristol Myers Squibb, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol Myers Squibb wasn't on the list.
While Bristol Myers Squibb currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.